This webinar will provide participants with scientific, policy, funding and community highlights from IAS 2025, the 13th IAS Conference on HIV Science, held in Kigali, Rwanda, in July. Attendees will gain a clearer understanding of the latest trends and emerging priorities in the global HIV response and hear reflections from stakeholders, including community voices.

Moderators

• Kenneth Ngure, School of Public Health, Jomo Kenyatta University of Agriculture and Technology and IAS — The International AIDS Society, Kenya
• Susan Shumba, Young Advocates for Inclusion Network and IAS — The International AIDS Society, Zimbabwe

Speakers

• Alexandra Calmy, Geneva University Hospitals (HUG) and IAS, Switzerland
• Gaston Devisich, Fundación Huésped, Argentina
• Doreen Moraa Moracha, Kenya

This 60-minute webinar is intended for communities, providers, policy makers and advocates for PrEP, HIV prevention and HIV testing. We will provide an overview of the key takeaways and new guidance from newly released Guidelines on lenacapavir for HIV prevention and testing strategies for long-acting injectable pre-exposure prophylaxis.

Thursday 28 August 2025 at 13:00 – 14:00 Geneva-time

Times in your location: 7:00 EDT / 12:00 WAT / 13:00 CEST / 13:00 SAST / 14:00 EEST / 16:30 IST / 18:00 ICT / 19:00 PHST

After registering, you will receive a confirmation email containing information about joining the webinar.

This is the first webinar in a three-part series: 

• Part 2 on 4 September 2025 focus on HIV testing (in partnership with PSI)
• Part 3 will focus on e-training for PrEP providers (in partnership with Jhpiego)

Further details about these webinars will be shared soon!

Join the International Community of Women Living with HIV Eastern Africa (ICWEA) to discuss the dapivirine vaginal ring, lenacapavir, and cabotegravir. Moderated by Lillian Mworeko and Dr. Lilian Benjamain Mwakyosi, speakers include:

• Michelle Rodolph, WHO
• Shannon Kowalski, Global Fund
• Leonard Solai, Population Council
• Yvette Raphael, Advocates for the Prevention of HIV in Africa
• Beryl Abade, youth champion and PrEP advocate

We are excited to invite you to our next TOWN HALL 📣 happening on Tuesday, August 12th at 10 AM EST!

We will be launching two critical resources:

• 📊 Market Assessment Report
• 📈 Key Population Long-Acting PrEP Demand Forecast

Gain insights from leading voices driving innovation in HIV prevention:

• ✨ Micheal Ighodaro – GBGMC
• ✨ Matt Hamilton – Avenir Health
• ✨ Catherine Verde-Hashim – AVAC

Together, we’ll explore what’s next for long-acting PrEP access, readiness, and demand among key populations globally.

👉 Click the registration link to register now!

Approved in July, lenacapavir for PrEP has tremendous potential to increase access and engagement in the United States, reaching individuals who have been unable to embrace PrEP in its previous formulations. The Choice Agenda and the HIV BLUPrInt team for a deep dive into rolling out lenacapavir (Yeztugo) in the US. Speakers summarized lessons, previewed existing resources, and called for expanded research and practice models that use lenacapavir as a lever to increase HIV prevention access, empowerment, and reach.

Recording / Slides / Resources

This is an ongoing series which occurs on the first Monday of alternating months and moderated by Drs. Patrick Sullivan (Emory Center for AIDS Research) and Kenneth Mayer (Harvard University Center for AIDS Research).

In August, AVAC Executive Director Mitchell Warren presented. Watch the presentation below. Download his slides.

Pre-exposure prophylaxis (PrEP) has emerged as a critical tool in the global HIV prevention response. Despite its proven efficacy, global uptake of oral PrEP has been slower than anticipated, falling short of UNAIDS’ 2025 targets. However, several countries have successfully scaled up oral PrEP, and in the process learnt significant lessons, many of which they are already applying to  introduce newer long-acting (LA) PrEP options such as the dapivirine vaginal ring (DVR) and injectable cabotegravir (CAB), and in planning for the introduction of the recently FDA approved twice yearly injectable lenacapavir (LEN).

This webinar aimed to increase momentum around ARV-based HIV prevention by highlighting key opportunities and challenges in scaling up PrEP. Drawing on findings from AVAC’s recent report, “Getting PrEP Rollout Right This Time: Lessons from the Field” (June 2025), the session shared country-level insights and effective interventions to support PrEP adherence and uptake. It reinforced the need for robust, context-driven strategies to accelerate equitable access to these critical prevention tools.

The specific objectives of this webinar were:

• Disseminate key findings from AVAC’s report, Getting PrEP Rollout Right This Time, with a focus on country experiences thematically analysed across the key stages of the Product Introduction Pathway.
• Share country-level evidence and insights on the introduction of new PrEP products, such as injectable cabotegravir (CAB) and the dapivirine vaginal ring (DVR) and preparations for the rollout of lenacapavir.
• Introduce an SOP to guide the adaptation of national PrEP policies for the inclusion of lenacapavir, supporting evidence-informed decision-making and implementation planning.
• Highlight effective interventions that support PrEP adherence and uptake, drawing on evidence products developed by the i2i programme.

Slides are available.